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Differential effects of scopolamine and chlorpromazine on 
REM and NREM sleep in normal male subiects* 
The study compares the effects of scopolamine, methscopolamine, and chlorpromazine on the 
EEG and the EOG in sleeping subjects. Saline was used as a control. Scopolamine 
hydrobromide (0.006 mg. per kilogram) clearly retarded the onset of stage REM. No 
immediate rebound was sei'n in the analysis of the sleep pattern for two hours after the first 
recording of this stage. The total amount of REM sleep during the full period of 
recording was therefore diminished. The decrease in REM resulted in an increased amount 
of stages I and II. No significant changes were observed in stages III or IV or in the periods 
of wakefulness. A significant increase in body movements was noted. Methscopolamine 
bromide (0.0055 mg. per kilogram) did not produce any substantial modification in the 
pattern of sleep. Chlorpromazine hydrochloride (0.4 mg. per kilogram) produced an increase 
of stage III activity apparently at the expense of stage H sleep. The observed changes 
further support a role of cholinergic mechanisms in human REM sleep. 
Teresa Sagales, M.D., Sergio Erill, M.D.,** and Edward F. Domino, M.D. 
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Michigan Neuropsychopharmacology Research Program, Department of Pharmacology, 
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The role of biogenic amines, particularly 
5-hydroxytryptamine ( 5HT) and norepi-
nephrine, in the mechanisms of sleep has 
been the subject of numerous studies. 7• 9 • 13 
Not as much attention has been paid to 
the possible participation of cholinergic 
mechanisms in the two major states of 
sleep-slow wave EEG ( NREM) and 
rapid-eye movements with EEG fast waves 
(REM )-or in the transition from one into 
another. Animal studies, however, suggest 
that cholinergic mechanisms are involved 
in sleep. The muscarinic cholinergic antag-
onist atropine has been reported to suppress 
REM sleep in the cat. 7• 8 Other qualitative 
differences have been shown in this species 
depending upon the doses employed. On 
the other hand, direct injection of oxo-
tremorine or carbachol into the brainstem 
reticular formation induces REM sleep in 
the cat.1 • 4 
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To date no reports are available on the 
effects of muscarinic cholinergic antago-
nists on the human sleep cycle. Scopol-
amine, whose central nervous system ef-
fects are well recognized, was considered 
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an appropriate tool to elucidate the role 
of a cholinergic sleep mechanism in man, 
especially since it is often included in 
over-the-counter sleep-inducing prepara-
tions. Clinically, it has been noted that 
scopolamine induces "dreamless" sleep.5 
This could be due to a decrease in stage 
REM or to a decrease in dream recall. 
The quaternary nitrogen derivative of 
scopolamine, methscopolamine, which has 
negligible central nervous system effects 
but even greater peripheral effects, 16 was 
used to determine the relative importance 
of central and peripheral cholinergic block-
ing effects on sleep. The a-adrenergic an-
tagonist chlorpromazine also produces se-
dation and EEG effects similar to those 
of scopolamine in the waking state. In 
this study it was used in clinically similar 
dosage to compare its effects with those of 
scopolamine. 
Methods 
Eight young healthy men, aged 21 to 
29, participated in these experiments after 
a complete history and physical examina-
tion had been obtained. The presence of 
basal alpha rhythm in the occipital areas 
during a resting EEG record was required 
for the acceptance of each subject into the 
study. The participants were instructed to 
abstain from alcohol or any other pharma-
cologically active substance during the 24 
hours prior to the beginning of the experi-
ment. No coffee or tobacco was permitted 
after 7. P.M. The first night of sleep was 
used for habituation. The recordings were 
made in a sound-attenuated, temperature-
controlled chamber. Electrodes for poly-
graphic recordings were placed in the 
usual positions (see below) but a contin-
uous all-night recording was not made. The 
subjects did not know that this was the 
case, inasmuch as they were isolated in 
the recording chamber. The second night 
was used for the baseline recordings ("no 
medication" night). After the second night, 
a sequence of saline, methscopolamine Br 
( 0.0055 mg. per kilogram), no medication, 
scopolamine HBr ( 0.006 mg. per kilo-
gram), no medication, and chlorpromazine 
HCl ( 0.4 mg. per kilogram) injections 
followed in four of the individuals. In the 
other four subjects only two drugs ( scopo-
lamine and chlorpromazine or scopolamine 
and methscopolamine) were used. "No 
medication" nights were intercalated in all 
instances in order to avoid overlapping in 
drug effects. 
Recording schedule. The subjects en-
tered the sleep laboratory at 9:45 P.M. 
From 9:45 to 11:00 P.M. the polygraph elec-
trodes were applied and an initial calibra-
tion of the polygraph was performed. A 
polygraph record was obtained with the 
subject keeping his eyes open, blinking, 
and also with his eyes closed. At approxi-
mately 11:00 P.M. the scheduled injection 
was given in accordance with the experi-
mental design described above. In all cases 
the intramuscular route was used. Injec-
tions were given low in the deltoid muscle 
(providing opportunity for use of a tourni-
quet if necessary). Following injection, the 
lights in the sound-attenuated chamber 
were turned off and a continuous poly-
graph recording was begun. This lasted 
until 6:30 A.M. During all recording peri-
ods the room temperature was kept at a 
comfortable level, according to indivdual 
subject preferences. An intercom was avail-
able for two-way communication. Every 
effort was made to achieve a comfortable 
and "naturaf' environment for each indi-
vidual, including the use of light or heavy 
pajamas, blankets, pillows, night lights, 
and the like, according to individual pref-
erence. All the drugs used in this study 
were prepared by the University Hospital 
pharmacy. The final volume to be injected 
was adjusted to 1.5 mi. in all cases. 
Electrode placement. At the beginning 
of each recording night, silver disc scalp 
electrodes were placed at positions F 3, C3, 
G1, P3 and 01 as defined by the 10-20 
International System.6 Beckman self-ad-
hering electrodes at F p1, the outer canthi 
of both eyes and submentally, served as 
ground, electrooculogram ( EOG) and 
electromyogram (EMG), respectively. Two 
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Telectrode self-adhering electrodes placed 
on the lobule of each ear and connected 
together served as reference. EEG, EMG, 
and EOG on an 8 channel Grass polygraph 
were recorded outside the sleeping cham-
ber. A paper speed of 15 mrn. per second 
and calibration of 50 tt V per centimeter 
were used except for the EMG channel, 
which was calibrated at 10 fL V per centi-
meter, and the EOG, which was calibrated 
at 100 fL V per centimeter. 
Scoring of sleep polygraph records. 
Modified criteria of Dement and Kleitman3 
and Williams and co-workers17 were used. 
The entire sleep record of each night was 
divided into one-minute epochs, each 
epoch being scored as one of the follow-
ing: wakefulness, stages I, II, III, IV, 
REM, or body movements. These features 
were scored as follows: Wakefulness (stage 
W), active awake, was characterized by 
low-voltage fast EEG patterns, EMG ac-
tivity, and eye movements; quiet awake 
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had a lower EMG and more than 50 per 
cent alpha rhythm ( 7.5 to 12.5 Hz.). Stage 
I was characterized by a low-voltage fast 
EEG pattern with less than 50 per cent 
alpha rhythm. Stage II contained at least 
two well-defined sleep spindles or two "K" 
complexes or one of each and no more 
than 20 per cent delta activity ( frequen-
cies from 0.5 to 4 Hz. and amplitudes of 
30 or more tt V). Stage III contained more 
than 20 per cent but less than 50 per cent 
delta activity. Stage IV contained more 
than 50 per cent delta activity. Stage REM 
was characterized by low-voltage, fast-
frequency activity, a decrease in the EMG, 
and large amplitude eye movements. Re-
cording of the EMG and EOG was ex-
tremely important in distinguishing epochs 
of quiet awake, stage I, and stage REM. 
BM (body movements): When muscle 
tremor artifact occupied more than two-
thirds of an epoch, that epoch was classi-
fied as BM. Stage REM: Rapid eye move-
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Fig. 1. Effects of saline on the distribution of stages of sleep in man ( 8 volunteers). On 
the x axis is plotted the time from onset of recording to awakening 450 minutes later. The 
y axis shows the number of subjects in a given stage of sleep in which one small square 
represents one subject. The no medication vs. saline data should be compared visually for 
each stage. Note that in general there are no marked differences. 
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Table I. Effects of single doses of saline, scopolamine, methscopolamine, and 
chloropromazine on stages of sleep in man 
Stages of sleep (mean per cent± S.E.) 
Drug 
No medication 
Saline 
Scopolamine HBr 
0.006 mg. per 
kilogram 
Methscopolamine 
Br 0.0055 mg. 
per kilogram 
Chlorpromazine 
HCl 0.4 mg. 
per kilogram 
"P <0.05. 
tP <0.01. 
tP <0.001. 
6 
6 
3.9 ± 1.4 5.6 ± 2.3 
4.3 ± 1.0 2.8 ± 0.8 
3.5± 0.8 8.4 ± 1.7" 
6.0 ± 0.9 3.3 ± 0.8 
3.6 ± 0.6 2.0 ± 0.2 
II I III IV REM 
44.0± 2.9 11.5 ± 1.5 8.3 ± 1.3" 20.9 ± 2.0 
39.4 ± 1.3 9.8 ± 1.4 13.7 ± 1.5 22.8 ± 1.6 
49.7 ± 1.7t 9.4 ± 1.2 13.7 ± 1.3 6.9 ± l.Ot 
39.5 ± 2.9 10.5 ± 0.6 11.8 ± 2.3 24.7 ± 1.4 
33.6 ± 1.6" 17.6 ± 2.lf 13.0 ± 1.6 25.7 ± 1.8 
Table II. Effects of single doses of saline, scopolamine, methscopolamine, and 
chlorpromazine on mean per cent of NREM and REM sleep, body movements 
(BM), and number of eye movements in man 
Drug N I NREM 
No medication 8 69.6 ± 2.0 
Saline 8 66.0 ± 1.9 
Scopolamine HBr 0.006 10 81.5 ± 2.3t 
mg. per kilogram 
Methscopolamine Br 0.0055 6 65.3 ± 0.6 
mg. per kilogram 
Chlorpromazine HCl 0.4 6 66.5 ± 3.1 
mg. per kilogram 
0 P <0.01. 
tP <0.001. 
ments during stage REM were defined as 
such when the deflection in the EOG re-
cording was equal to or greater than 50 
fLY. 
Results 
For comparative purposes, the night 
when saline was injected was used as con-
trol in all cases. The duration and distri-
bution of the sleep stages in the saline 
night were quite similar to the no medica-
tion night (Fig. 1). The x axis represents 
the time from onset of recording time to 
awakening 450 minutes later. The y axis 
Total number 
eye move-
REM BM ments 
20.9 ± 2.0 1.4 ± 0.3 739.2± 77.9 
22.8 ± 1.6 1.1 ± 0.2 635.4 ± 86.9 
6.9 ± l.Of 4.7± 0.9" 114.8 ± 8.ot 
24.7 ± 1.4 1.4 ± 0.4 871.1 ± 95.2 
25.7 ± 1.8 0.9 ± 0.3 792.1 ± 165.7 
represents the number of subjects in a 
given stage of sleep, in which one small 
square represents one subject. The quanti-
tative data for each stage of sleep are given 
in Tables I and II. A significant increase 
in stage IV followed saline as compared to 
no medication ( p < 0.05). For this reason, 
all subsequent data were compared to the 
saline night. 
Effects of scopolamine. The most strik-
ing change induced by 0.006 mg. per kilo-
gram of scopolamine HBr was a delay in 
the onset of REM sleep. As noted in Fig. 
2, the onset of stage REM during the 
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Fig. 2. Effects of scopolamine on the distribution of stages of sleep in man ( 8 volunteers). 
The data are plotted as described in Fig. I. Note that scopolamine ( 0.006 mg. per kilogram, 
intramuscularly) caused a dramatic decrease in REM for most of the night. No rebound was 
observed for the period recorded. 
saline night took place during the second 
hour of sleep (mean time in our series 
was 105 minutes). In scopolamine-treated 
individuals there was a complete absence 
of REM sleep during the first 4% hours. 
The mean onset of REM for eight scopol-
amine-treated subjects occurred 327 min-
utes after the initiation of recording. Sub-
sequently, bursts of REM were present for 
the rest of the night (see Fig. 2). As noted 
in Tables I and II, the total amount of 
REM stage during the 7% hours of sleep 
was significantly reduced in comparison 
with the saline night (p < 0.001). Until 
the end of the recording period, no re-
bound in REM was seen. The concomitant 
increase in non-REM ( NREM) sleep ap-
peared mostly as an enhancement of stage 
II ( p < 0.001). The duration of stage I 
was also extended ( p < 0.05). A marked 
decrease in the total number of rapid eye 
movements during the night was observed. 
Inasmuch as rapid eye movements occur 
during stage REM, the ratio of eye move-
ments to minutes of stage REM was cal-
culated. This analysis showed that the 
number of eye movements during stage 
REM was diminished by the administra-
tion of scopolamine (ratio 6.0 for saline 
and 3.4 for scopolamine; p < 0.05). This 
was also observed when a comparison was 
made between the total number of rapid 
eye movements and the epochs of REM in 
which the rapid eye movements appear 
(ratio 9.4 for saline and 5.6 for scopol-
amine; p < 0.05). The number of body 
movements per night was increased by the 
administration of scopolamine (see Table 
II). 
Effects of methscopolamine. In contrast 
to the marked changes induced by scopol-
amine, injection of an equimolar dose of 
methscopolamine Br did not induce any 
substantial modification on the pattern of 
sleep, as noted in Fig. 3 and Tables I and 
II. 
Effects of chlorpromazine. Chlorproma-
zine in a dose of 0.4 mg. per kilogram did 
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Fig. 3. Lack of effects of methscopolamine on the distribution of stages of sleep in man 
( 6 volunteers). The data are plotted as described in Fig. 1. Note that methscopolamine 
( 0.0055 mg. per kilogram, intramuscularly) did not have any significant effect on REM in 
contrast to the marked effect of scopolamine (see Fig. 2). 
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Fig. 4. Effect of chlorpromazine on the distribution of stages of sleep in man ( 6 volunteers). 
The data are plotted as described in Fig. 1. Note that chlorpromazine ( 0.4 mg. per kilogram, 
intramuscularly) caused an increase in the amount of stage III. In this dose REM was not 
depressed in contrast to the dramatic effect of scopolamine (see Fig. 2). 
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not produce any change in the REM/ 
slow wave sleep ratio (see Table II). As 
noted in Fig. 4, no dramatic changes in 
the sleep cycle were observed with the 
possible exception of stage III. Chlorpro-
mazine induced an increase of stage III 
(from 9.8 per cent in the saline night to 
17.6 per cent in the chlorpromazine night; 
p < 0.01). This increase appeared to be 
at the expense of stage II sleep (which 
diminished from 39.4 to 33.6 per cent; 
p < 0.05). REM onset was slightly earlier 
in some subjects than after saline injection, 
but this was not consistent. The duration 
of the first period of stage REM was 
greater after chlorpromazine (mean 30 
minutes) than after saline (mean 20.5 
minutes). This difference, however, was 
not statistically significant with the num-
ber of subjects studied. 
Discussion 
The present study clearly shows that a 
centrally acting muscarinic cholinergic an-
tagonist, scopolamine, induces marked 
changes in the pattern of sleep in man. 
REM sleep is clearly reduced, the main 
effect of scopolamine being to delay its 
onset. This is counterbalanced by an in-
crease in stages I and II sleep. 
In contrast to the dramatic effects of 
scopolamine, chlorpromazine in similar 
single doses had negligible effects on REM 
sleep. An intramuscular dose of 0.4 mg. 
per kilogram is not large, although it clear-
ly has definite pharmacological effects in 
man. In this dose it has peripheral a-
adrenergic blocking effects and produces 
sedation. If this dose of chlorpromazine 
had central adrenergic blocking effects, it 
would suggest that monoamines are less 
important to initiating and maintaining 
REM than is acetylcholine, at least in man. 
The available evidence in favor of a mono-
aminergic participation in the mechanisms 
of REM sleep in the cat is impressive. 
Destruction of the caudal raphe (whose 
high concentration in 5HT is well known) 
is followed by a marked suppression of 
both NREM and REM sleep.10 Mono-
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amine oxidase inhibitors markedly sup-
press REM sleep.11 This is also the case 
with inhibitors of norepinephrine and 
5HT synthesis. 2 • 9 
Evidence in favor of a cholinergic 
mechanism in REM sleep is growing. Atro-
pine is able to suppress REM sleep in the 
cat,8 and pilocarpine enhances stage 
REM.18 Furthermore, facilitation of REM 
sleep is seen in pontine cats after physo-
stigmine, 8 and' direct injection of oxotre-
morine or carbachol into the brainstem 
reticular formation induces REM sleep in 
normal cats.1 • 4 Jouvet9 has interpreted this 
to mean that acetylcholine may act as a 
triggering mechanism for adrenergic neu-
rons in REM sleep. 
Our results with scopolamine further 
stress the importance of cholinergic mecha-
nisms in the physiology of sleep in man. 
The exact nature of this involvement re-
mains to be elucidated. The hypothesis of 
a triggering mechanism, as suggested by 
Jouvet, needs direct experimental evi-
dence. Further studies are necessary in or-
der to establish the effects and interactions 
of drugs with central cholinergic, adrener-
gic, and serotonergic activity on human 
sleep. 
Our results with chlorpromazine are in 
accord with those of others12• 15 using simi-
lar doses. There was a lack of correlation 
between the effects of chlorpromazine and 
scopolamine upon the sleep patterns, even 
though their effect on the EEG of awake 
individuals is relatively similar. Finally, 
from a clinical point of view, it is inter-
esting to note that scopolamine, often in-
cluded in sleep-inducing mixtures, does 
not produce physiological sleep. The fact 
that most drugs used as soporifics induce 
a REM-deprived sleep is well known.14 
Since tolerance to REM depression by 
barbiturates is well known, it would be of 
interest to detern1ine if similar tolerance 
to depression of REM occurs with daily 
doses of scopolamine given at bedtime. 
The authors would like to acknowledge the 
technical assistance of Mr. Gary Gossinger in this 
study. 
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